Indian Journal of Pharmacology Home 

AUTHORS«SQ» REPLY
[Download PDF]
Year : 2013  |  Volume : 45  |  Issue : 3  |  Page : 314-

Author's reply

Tanvir Samra 
 Dr. Ram Manohar Lohia Hospital, Baba Kharak Singh Marg, Connaught Place, New Delhi, India

Correspondence Address:
Tanvir Samra
Dr. Ram Manohar Lohia Hospital, Baba Kharak Singh Marg, Connaught Place, New Delhi
India




How to cite this article:
Samra T. Author's reply.Indian J Pharmacol 2013;45:314-314


How to cite this URL:
Samra T. Author's reply. Indian J Pharmacol [serial online] 2013 [cited 2020 Jul 14 ];45:314-314
Available from: http://www.ijp-online.com/text.asp?2013/45/3/314/111930


Full Text

Sir,

I agree that there are different studies both for and against the chemoprophylactic intake of oseltamivir in health care personal (HCP) with different levels of exposure to H1N1 infection.

But in our study, we have included those HCP who were following all other infection control measures also, such as use of personal protective equipment (PPE), frequent handwashing, etc.

In such circumstances, the intake of oseltamivir does not give any added benefit.

Their is a need to carry out further studies for prophylactic intake of oseltamivir in other HCP who are at risk and are not using other infection control measures appropriately.